Stem definition | Drug id | CAS RN |
---|---|---|
HIV protease inhibitors | 254 | 198904-31-3 |
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
0.30 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 7 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 8.11 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 64 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
March 2, 2004 | EMA | ||
June 20, 2003 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Abortion spontaneous | 977.41 | 26.35 | 336 | 8164 | 41436 | 50555188 |
Foetal exposure during pregnancy | 863.29 | 26.35 | 276 | 8224 | 27083 | 50569541 |
Maternal exposure during pregnancy | 762.91 | 26.35 | 417 | 8083 | 159361 | 50437263 |
Exposure during pregnancy | 489.39 | 26.35 | 284 | 8216 | 120731 | 50475893 |
Abortion induced | 402.81 | 26.35 | 120 | 8380 | 9224 | 50587400 |
Premature baby | 345.60 | 26.35 | 126 | 8374 | 18211 | 50578413 |
Live birth | 336.41 | 26.35 | 120 | 8380 | 16288 | 50580336 |
Stillbirth | 276.35 | 26.35 | 81 | 8419 | 5871 | 50590753 |
Pregnancy | 258.33 | 26.35 | 117 | 8383 | 29460 | 50567164 |
Caesarean section | 245.41 | 26.35 | 94 | 8406 | 15545 | 50581079 |
Hyperbilirubinaemia | 242.42 | 26.35 | 82 | 8418 | 9488 | 50587136 |
Premature delivery | 230.29 | 26.35 | 101 | 8399 | 23562 | 50573062 |
Drug interaction | 162.42 | 26.35 | 183 | 8317 | 199438 | 50397186 |
Foetal death | 149.47 | 26.35 | 55 | 8445 | 8125 | 50588499 |
Foetal growth restriction | 122.70 | 26.35 | 45 | 8455 | 6582 | 50590042 |
Pregnancy on contraceptive | 119.14 | 26.35 | 29 | 8471 | 1023 | 50595601 |
Normal newborn | 118.60 | 26.35 | 44 | 8456 | 6647 | 50589977 |
Virologic failure | 117.21 | 26.35 | 31 | 8469 | 1533 | 50595091 |
Congenital naevus | 109.29 | 26.35 | 20 | 8480 | 166 | 50596458 |
Ventricular septal defect | 103.75 | 26.35 | 35 | 8465 | 4006 | 50592618 |
Renal colic | 100.40 | 26.35 | 26 | 8474 | 1183 | 50595441 |
Viral mutation identified | 97.30 | 26.35 | 27 | 8473 | 1602 | 50595022 |
Immune reconstitution inflammatory syndrome | 96.75 | 26.35 | 36 | 8464 | 5480 | 50591144 |
Viral load increased | 96.53 | 26.35 | 25 | 8475 | 1138 | 50595486 |
Jaundice | 95.67 | 26.35 | 58 | 8442 | 26371 | 50570253 |
Premature rupture of membranes | 95.65 | 26.35 | 34 | 8466 | 4546 | 50592078 |
Cushing's syndrome | 94.93 | 26.35 | 22 | 8478 | 626 | 50595998 |
Supernumerary nipple | 93.87 | 26.35 | 15 | 8485 | 48 | 50596576 |
Nephrolithiasis | 93.00 | 26.35 | 63 | 8437 | 34630 | 50561994 |
Low set ears | 89.77 | 26.35 | 18 | 8482 | 252 | 50596372 |
Acoustic stimulation tests abnormal | 87.56 | 26.35 | 15 | 8485 | 81 | 50596543 |
Low birth weight baby | 76.88 | 26.35 | 31 | 8469 | 5850 | 50590774 |
Drug ineffective | 76.08 | 26.35 | 22 | 8478 | 819311 | 49777313 |
Congenital hydrocephalus | 75.29 | 26.35 | 14 | 8486 | 128 | 50596496 |
Lipodystrophy acquired | 74.67 | 26.35 | 21 | 8479 | 1308 | 50595316 |
Spina bifida | 72.77 | 26.35 | 18 | 8482 | 679 | 50595945 |
Blood bilirubin increased | 69.20 | 26.35 | 51 | 8449 | 31987 | 50564637 |
Twin pregnancy | 69.01 | 26.35 | 19 | 8481 | 1094 | 50595530 |
Pre-eclampsia | 64.41 | 26.35 | 30 | 8470 | 8014 | 50588610 |
Polydactyly | 64.34 | 26.35 | 14 | 8486 | 297 | 50596327 |
Patent ductus arteriosus | 63.60 | 26.35 | 24 | 8476 | 3796 | 50592828 |
Trisomy 18 | 63.58 | 26.35 | 10 | 8490 | 28 | 50596596 |
Placenta praevia | 62.61 | 26.35 | 17 | 8483 | 929 | 50595695 |
Placental insufficiency | 61.92 | 26.35 | 18 | 8482 | 1263 | 50595361 |
Adrenal suppression | 59.26 | 26.35 | 16 | 8484 | 856 | 50595768 |
Blood bilirubin unconjugated increased | 58.53 | 26.35 | 13 | 8487 | 304 | 50596320 |
Pain | 58.50 | 26.35 | 13 | 8487 | 578890 | 50017734 |
Gestational diabetes | 57.17 | 26.35 | 27 | 8473 | 7438 | 50589186 |
Drug resistance | 52.09 | 26.35 | 35 | 8465 | 18954 | 50577670 |
Premature labour | 51.59 | 26.35 | 29 | 8471 | 11447 | 50585177 |
Pathogen resistance | 51.15 | 26.35 | 23 | 8477 | 5666 | 50590958 |
Trisomy 21 | 50.94 | 26.35 | 12 | 8488 | 367 | 50596257 |
Oligohydramnios | 50.91 | 26.35 | 23 | 8477 | 5727 | 50590897 |
Fanconi syndrome acquired | 49.21 | 26.35 | 14 | 8486 | 909 | 50595715 |
CD4 lymphocytes decreased | 48.24 | 26.35 | 15 | 8485 | 1324 | 50595300 |
Renal tubular disorder | 46.78 | 26.35 | 17 | 8483 | 2420 | 50594204 |
Polyhydramnios | 45.97 | 26.35 | 16 | 8484 | 2009 | 50594615 |
Macrocephaly | 45.56 | 26.35 | 8 | 8492 | 51 | 50596573 |
Osteonecrosis | 42.32 | 26.35 | 33 | 8467 | 22484 | 50574140 |
Congenital central nervous system anomaly | 41.92 | 26.35 | 10 | 8490 | 323 | 50596301 |
Hydrocephalus | 41.91 | 26.35 | 19 | 8481 | 4769 | 50591855 |
Blood HIV RNA increased | 41.70 | 26.35 | 11 | 8489 | 538 | 50596086 |
Fatigue | 41.48 | 26.35 | 35 | 8465 | 707566 | 49889058 |
Foetal distress syndrome | 40.91 | 26.35 | 13 | 8487 | 1232 | 50595392 |
Ultrasound antenatal screen abnormal | 39.57 | 26.35 | 8 | 8492 | 117 | 50596507 |
Left ventricular dilatation | 39.43 | 26.35 | 10 | 8490 | 418 | 50596206 |
Fall | 39.31 | 26.35 | 5 | 8495 | 334927 | 50261697 |
Eosinophilia | 38.71 | 26.35 | 29 | 8471 | 18623 | 50578001 |
Microcephaly | 37.38 | 26.35 | 11 | 8489 | 805 | 50595819 |
Coarctation of the aorta | 36.54 | 26.35 | 10 | 8490 | 563 | 50596061 |
Ectopic pregnancy | 36.50 | 26.35 | 14 | 8486 | 2313 | 50594311 |
Breast disorder | 34.73 | 26.35 | 13 | 8487 | 2009 | 50594615 |
Dyspnoea | 34.68 | 26.35 | 25 | 8475 | 547583 | 50049041 |
Mitochondrial cytopathy | 34.54 | 26.35 | 8 | 8492 | 227 | 50596397 |
Ocular icterus | 34.29 | 26.35 | 15 | 8485 | 3460 | 50593164 |
Amniotic cavity infection | 33.54 | 26.35 | 11 | 8489 | 1152 | 50595472 |
Hepatic cytolysis | 32.47 | 26.35 | 19 | 8481 | 8084 | 50588540 |
Alpha 1 foetoprotein abnormal | 32.35 | 26.35 | 6 | 8494 | 54 | 50596570 |
Calculus urinary | 31.57 | 26.35 | 10 | 8490 | 938 | 50595686 |
Hepatitis | 30.96 | 26.35 | 32 | 8468 | 31421 | 50565203 |
Congenital anomaly | 30.65 | 26.35 | 11 | 8489 | 1510 | 50595114 |
Joint swelling | 30.43 | 26.35 | 3 | 8497 | 245283 | 50351341 |
Encephalomalacia | 29.39 | 26.35 | 8 | 8492 | 441 | 50596183 |
Congenital genital malformation female | 29.34 | 26.35 | 5 | 8495 | 26 | 50596598 |
Maternal drugs affecting foetus | 28.87 | 26.35 | 15 | 8485 | 5062 | 50591562 |
Foetal anaemia | 28.74 | 26.35 | 5 | 8495 | 30 | 50596594 |
Isoimmune haemolytic disease | 28.60 | 26.35 | 5 | 8495 | 31 | 50596593 |
Epidural lipomatosis | 28.56 | 26.35 | 6 | 8494 | 107 | 50596517 |
Conduction disorder | 28.41 | 26.35 | 10 | 8490 | 1298 | 50595326 |
Oesophageal atresia | 28.12 | 26.35 | 8 | 8492 | 519 | 50596105 |
Congenital skin dimples | 28.10 | 26.35 | 6 | 8494 | 116 | 50596508 |
Placental chorioangioma | 28.00 | 26.35 | 4 | 8496 | 4 | 50596620 |
Subchorionic haematoma | 27.77 | 26.35 | 6 | 8494 | 123 | 50596501 |
Cerebral ventricle dilatation | 27.58 | 26.35 | 9 | 8491 | 928 | 50595696 |
Placental disorder | 27.54 | 26.35 | 10 | 8490 | 1420 | 50595204 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 1247.28 | 17.38 | 927 | 14292 | 196458 | 29362850 |
Depression | 1159.11 | 17.38 | 650 | 14569 | 84497 | 29474811 |
Nephrolithiasis | 453.44 | 17.38 | 233 | 14986 | 25101 | 29534207 |
Hyperbilirubinaemia | 399.50 | 17.38 | 181 | 15038 | 14753 | 29544555 |
Foetal exposure during pregnancy | 379.73 | 17.38 | 229 | 14990 | 33638 | 29525670 |
Lipodystrophy acquired | 370.64 | 17.38 | 113 | 15106 | 2981 | 29556327 |
Renal colic | 333.28 | 17.38 | 90 | 15129 | 1515 | 29557793 |
Jaundice | 252.88 | 17.38 | 168 | 15051 | 29128 | 29530180 |
Loss of personal independence in daily activities | 239.36 | 17.38 | 154 | 15065 | 25286 | 29534022 |
Renal tubular disorder | 212.09 | 17.38 | 81 | 15138 | 4271 | 29555037 |
Blood bilirubin increased | 167.44 | 17.38 | 139 | 15080 | 33754 | 29525554 |
Mitochondrial toxicity | 166.34 | 17.38 | 58 | 15161 | 2353 | 29556955 |
Fanconi syndrome acquired | 153.28 | 17.38 | 51 | 15168 | 1791 | 29557517 |
Immune reconstitution inflammatory syndrome | 148.74 | 17.38 | 75 | 15144 | 7727 | 29551581 |
Eyelid ptosis | 123.34 | 17.38 | 58 | 15161 | 5128 | 29554180 |
Psychiatric decompensation | 122.59 | 17.38 | 41 | 15178 | 1463 | 29557845 |
Depression suicidal | 119.84 | 17.38 | 39 | 15180 | 1276 | 29558032 |
Calculus urinary | 116.62 | 17.38 | 37 | 15182 | 1114 | 29558194 |
Tearfulness | 111.48 | 17.38 | 39 | 15180 | 1597 | 29557711 |
Ocular icterus | 103.91 | 17.38 | 42 | 15177 | 2573 | 29556735 |
Virologic failure | 100.46 | 17.38 | 42 | 15177 | 2805 | 29556503 |
Lipoatrophy | 90.24 | 17.38 | 25 | 15194 | 464 | 29558844 |
Blood bilirubin unconjugated increased | 86.93 | 17.38 | 25 | 15194 | 534 | 29558774 |
HIV-associated neurocognitive disorder | 85.94 | 17.38 | 22 | 15197 | 297 | 29559011 |
Viral load increased | 85.19 | 17.38 | 34 | 15185 | 2015 | 29557293 |
Blood HIV RNA increased | 79.84 | 17.38 | 27 | 15192 | 997 | 29558311 |
Osteonecrosis | 78.49 | 17.38 | 61 | 15158 | 13458 | 29545850 |
Fanconi syndrome | 75.17 | 17.38 | 29 | 15190 | 1569 | 29557739 |
Premature baby | 73.29 | 17.38 | 65 | 15154 | 17215 | 29542093 |
Heterotaxia | 72.46 | 17.38 | 16 | 15203 | 108 | 29559200 |
Trisomy 21 | 71.43 | 17.38 | 21 | 15198 | 486 | 29558822 |
Proteinuria | 70.14 | 17.38 | 61 | 15158 | 15743 | 29543565 |
Cushing's syndrome | 67.15 | 17.38 | 19 | 15200 | 382 | 29558926 |
Depressive symptom | 66.24 | 17.38 | 27 | 15192 | 1690 | 29557618 |
Diplopia | 65.76 | 17.38 | 55 | 15164 | 13463 | 29545845 |
CD4 lymphocytes decreased | 64.64 | 17.38 | 26 | 15193 | 1572 | 29557736 |
Death | 63.63 | 17.38 | 50 | 15169 | 342034 | 29217274 |
Single umbilical artery | 63.56 | 17.38 | 16 | 15203 | 201 | 29559107 |
Cholelithiasis | 61.44 | 17.38 | 61 | 15158 | 18611 | 29540697 |
Osteoporosis | 61.23 | 17.38 | 48 | 15171 | 10721 | 29548587 |
Paranoia | 60.47 | 17.38 | 46 | 15173 | 9831 | 29549477 |
Kaposi's sarcoma | 60.46 | 17.38 | 21 | 15198 | 841 | 29558467 |
Glycosuria | 57.93 | 17.38 | 22 | 15197 | 1140 | 29558168 |
Viral mutation identified | 56.62 | 17.38 | 27 | 15192 | 2461 | 29556847 |
Psychomotor skills impaired | 54.89 | 17.38 | 27 | 15192 | 2634 | 29556674 |
Psychotic disorder | 51.82 | 17.38 | 58 | 15161 | 20296 | 29539012 |
Cortisol decreased | 49.76 | 17.38 | 18 | 15201 | 813 | 29558495 |
Hypotension | 49.67 | 17.38 | 19 | 15200 | 194335 | 29364973 |
Suicidal ideation | 49.14 | 17.38 | 74 | 15145 | 34642 | 29524666 |
Nephropathy toxic | 48.70 | 17.38 | 42 | 15177 | 10714 | 29548594 |
Ureterolithiasis | 48.17 | 17.38 | 22 | 15197 | 1818 | 29557490 |
Drug ineffective | 46.65 | 17.38 | 72 | 15147 | 363098 | 29196210 |
Hypertriglyceridaemia | 43.97 | 17.38 | 34 | 15185 | 7441 | 29551867 |
Blood antidiuretic hormone increased | 42.73 | 17.38 | 9 | 15210 | 47 | 29559261 |
Chordee | 40.99 | 17.38 | 9 | 15210 | 59 | 29559249 |
Nephrocalcinosis | 40.88 | 17.38 | 14 | 15205 | 537 | 29558771 |
Vanishing bile duct syndrome | 39.99 | 17.38 | 14 | 15205 | 574 | 29558734 |
Hypophosphataemia | 38.03 | 17.38 | 32 | 15187 | 7892 | 29551416 |
Drug resistance | 37.98 | 17.38 | 51 | 15168 | 21489 | 29537819 |
Off label use | 37.28 | 17.38 | 61 | 15158 | 300739 | 29258569 |
Fall | 36.65 | 17.38 | 23 | 15196 | 177155 | 29382153 |
Pneumonia | 35.14 | 17.38 | 70 | 15149 | 320102 | 29239206 |
Neonatal hyponatraemia | 34.30 | 17.38 | 8 | 15211 | 71 | 29559237 |
Exposure during pregnancy | 33.94 | 17.38 | 31 | 15188 | 8523 | 29550785 |
Adrenal suppression | 33.64 | 17.38 | 12 | 15207 | 520 | 29558788 |
HIV wasting syndrome | 33.00 | 17.38 | 8 | 15211 | 85 | 29559223 |
Congenital hydrocephalus | 32.83 | 17.38 | 8 | 15211 | 87 | 29559221 |
Febrile neutropenia | 32.11 | 17.38 | 9 | 15210 | 112231 | 29447077 |
Pathogen resistance | 31.39 | 17.38 | 29 | 15190 | 8087 | 29551221 |
Dyspnoea | 31.28 | 17.38 | 77 | 15142 | 326655 | 29232653 |
Congenital naevus | 31.13 | 17.38 | 6 | 15213 | 18 | 29559290 |
Hepatitis C | 30.96 | 17.38 | 30 | 15189 | 8880 | 29550428 |
Hepatitis | 30.39 | 17.38 | 45 | 15174 | 20738 | 29538570 |
Psychomotor retardation | 30.39 | 17.38 | 19 | 15200 | 2957 | 29556351 |
Enanthema | 30.05 | 17.38 | 10 | 15209 | 351 | 29558957 |
Hepatic cirrhosis | 29.85 | 17.38 | 37 | 15182 | 14407 | 29544901 |
Hypothalamic pituitary adrenal axis suppression | 29.53 | 17.38 | 8 | 15211 | 136 | 29559172 |
Dysphagia | 29.52 | 17.38 | 78 | 15141 | 54848 | 29504460 |
Crystal urine | 29.08 | 17.38 | 7 | 15212 | 72 | 29559236 |
Anomalous pulmonary venous connection | 28.91 | 17.38 | 7 | 15212 | 74 | 29559234 |
Disease progression | 28.78 | 17.38 | 4 | 15215 | 81912 | 29477396 |
CSF virus identified | 28.70 | 17.38 | 6 | 15213 | 30 | 29559278 |
Low birth weight baby | 28.29 | 17.38 | 25 | 15194 | 6583 | 29552725 |
Completed suicide | 28.22 | 17.38 | 6 | 15213 | 90240 | 29469068 |
Hydronephrosis | 27.75 | 17.38 | 28 | 15191 | 8702 | 29550606 |
Biliary colic | 27.61 | 17.38 | 12 | 15207 | 881 | 29558427 |
CSF HIV escape syndrome | 27.50 | 17.38 | 8 | 15211 | 178 | 29559130 |
Trimethylaminuria | 27.38 | 17.38 | 5 | 15214 | 10 | 29559298 |
Haemophilic arthropathy | 26.66 | 17.38 | 7 | 15212 | 105 | 29559203 |
Alpha 1 foetoprotein abnormal | 26.20 | 17.38 | 5 | 15214 | 14 | 29559294 |
Alanine aminotransferase increased | 26.02 | 17.38 | 88 | 15131 | 70856 | 29488452 |
Renal failure | 25.78 | 17.38 | 125 | 15094 | 118474 | 29440834 |
Tubulointerstitial nephritis | 25.51 | 17.38 | 38 | 15181 | 17605 | 29541703 |
Jarisch-Herxheimer reaction | 25.48 | 17.38 | 9 | 15210 | 379 | 29558929 |
Hepatic cytolysis | 25.13 | 17.38 | 26 | 15193 | 8321 | 29550987 |
Cardiac failure congestive | 24.13 | 17.38 | 5 | 15214 | 76576 | 29482732 |
Intestinal malrotation | 23.92 | 17.38 | 5 | 15214 | 25 | 29559283 |
Persistent left superior vena cava | 23.52 | 17.38 | 4 | 15215 | 4 | 29559304 |
Hyperadrenocorticism | 23.50 | 17.38 | 6 | 15213 | 80 | 29559228 |
Blood pressure increased | 22.88 | 17.38 | 5 | 15214 | 73798 | 29485510 |
Umbilical cord abnormality | 21.79 | 17.38 | 5 | 15214 | 41 | 29559267 |
Heart transplant rejection | 21.73 | 17.38 | 11 | 15208 | 1140 | 29558168 |
Renal tubular dysfunction | 21.24 | 17.38 | 8 | 15211 | 405 | 29558903 |
Foetal chromosome abnormality | 21.01 | 17.38 | 4 | 15215 | 11 | 29559297 |
Acquired immunodeficiency syndrome | 20.98 | 17.38 | 8 | 15211 | 419 | 29558889 |
Hyperlipidaemia | 20.96 | 17.38 | 29 | 15190 | 12561 | 29546747 |
Constipation | 20.72 | 17.38 | 17 | 15202 | 114143 | 29445165 |
Ventricular septal defect | 20.64 | 17.38 | 16 | 15203 | 3513 | 29555795 |
Sepsis | 20.51 | 17.38 | 26 | 15193 | 142656 | 29416652 |
Wrong dose | 20.37 | 17.38 | 8 | 15211 | 454 | 29558854 |
Acute stress disorder | 20.32 | 17.38 | 6 | 15213 | 141 | 29559167 |
Adrenogenital syndrome | 20.31 | 17.38 | 5 | 15214 | 57 | 29559251 |
Facial wasting | 20.16 | 17.38 | 6 | 15213 | 145 | 29559163 |
Atrial fibrillation | 20.10 | 17.38 | 15 | 15204 | 105631 | 29453677 |
Drug abuse | 20.05 | 17.38 | 8 | 15211 | 79875 | 29479433 |
Cardiac failure | 19.80 | 17.38 | 8 | 15211 | 79279 | 29480029 |
Drug level increased | 19.72 | 17.38 | 35 | 15184 | 18752 | 29540556 |
Foetal monitoring abnormal | 19.72 | 17.38 | 3 | 15216 | 0 | 29559308 |
Pancreatitis | 19.55 | 17.38 | 50 | 15169 | 34464 | 29524844 |
Portal fibrosis | 19.39 | 17.38 | 7 | 15212 | 314 | 29558994 |
Encephalitis | 19.30 | 17.38 | 20 | 15199 | 6410 | 29552898 |
Right aortic arch | 19.13 | 17.38 | 4 | 15215 | 20 | 29559288 |
Mitochondrial cytopathy | 19.09 | 17.38 | 6 | 15213 | 175 | 29559133 |
Encephalitis viral | 19.02 | 17.38 | 10 | 15209 | 1122 | 29558186 |
Congenital hepatomegaly | 18.97 | 17.38 | 4 | 15215 | 21 | 29559287 |
Anogenital warts | 18.81 | 17.38 | 8 | 15211 | 557 | 29558751 |
Infection | 18.76 | 17.38 | 8 | 15211 | 76743 | 29482565 |
Anal cancer | 18.54 | 17.38 | 7 | 15212 | 357 | 29558951 |
Myoglobin blood increased | 18.53 | 17.38 | 12 | 15207 | 1983 | 29557325 |
Erythema elevatum diutinum | 18.38 | 17.38 | 4 | 15215 | 25 | 29559283 |
Thalassaemia alpha | 18.38 | 17.38 | 4 | 15215 | 25 | 29559283 |
Genitalia external ambiguous | 18.13 | 17.38 | 6 | 15213 | 207 | 29559101 |
Deafness congenital | 18.03 | 17.38 | 5 | 15214 | 93 | 29559215 |
Renal impairment | 17.85 | 17.38 | 86 | 15133 | 81247 | 29478061 |
Foetal cystic hygroma | 17.64 | 17.38 | 3 | 15216 | 3 | 29559305 |
Polymicrogyria | 17.64 | 17.38 | 3 | 15216 | 3 | 29559305 |
Nasal septum deviation | 17.63 | 17.38 | 9 | 15210 | 950 | 29558358 |
Aspartate aminotransferase increased | 17.59 | 17.38 | 69 | 15150 | 59656 | 29499652 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 1162.62 | 17.70 | 887 | 17018 | 361196 | 64119631 |
Abortion spontaneous | 856.55 | 17.70 | 305 | 17600 | 24838 | 64455989 |
Depression | 683.01 | 17.70 | 493 | 17412 | 182798 | 64298029 |
Maternal exposure during pregnancy | 563.20 | 17.70 | 343 | 17562 | 95541 | 64385286 |
Hyperbilirubinaemia | 562.07 | 17.70 | 214 | 17691 | 20991 | 64459836 |
Lipodystrophy acquired | 475.62 | 17.70 | 127 | 17778 | 3900 | 64476927 |
Nephrolithiasis | 463.23 | 17.70 | 231 | 17674 | 43452 | 64437375 |
Abortion induced | 317.43 | 17.70 | 103 | 17802 | 6285 | 64474542 |
Jaundice | 314.01 | 17.70 | 185 | 17720 | 48327 | 64432500 |
Renal colic | 305.50 | 17.70 | 80 | 17825 | 2272 | 64478555 |
Exposure during pregnancy | 279.18 | 17.70 | 205 | 17700 | 77470 | 64403357 |
Stillbirth | 240.74 | 17.70 | 73 | 17832 | 3560 | 64477267 |
Immune reconstitution inflammatory syndrome | 233.35 | 17.70 | 98 | 17807 | 12372 | 64468455 |
Renal tubular disorder | 220.18 | 17.70 | 77 | 17828 | 5910 | 64474917 |
Mitochondrial toxicity | 208.07 | 17.70 | 61 | 17844 | 2645 | 64478182 |
Live birth | 199.47 | 17.70 | 85 | 17820 | 11119 | 64469708 |
Blood bilirubin increased | 186.84 | 17.70 | 143 | 17762 | 57410 | 64423417 |
Pregnancy | 176.77 | 17.70 | 95 | 17810 | 20770 | 64460057 |
Caesarean section | 176.12 | 17.70 | 78 | 17827 | 11196 | 64469631 |
Fanconi syndrome acquired | 174.87 | 17.70 | 52 | 17853 | 2369 | 64478458 |
Premature delivery | 172.65 | 17.70 | 90 | 17815 | 18499 | 64462328 |
Viral mutation identified | 170.47 | 17.70 | 55 | 17850 | 3291 | 64477536 |
Loss of personal independence in daily activities | 169.96 | 17.70 | 149 | 17756 | 72305 | 64408522 |
Viral load increased | 160.61 | 17.70 | 49 | 17856 | 2438 | 64478389 |
Virologic failure | 156.51 | 17.70 | 52 | 17853 | 3414 | 64477413 |
Calculus urinary | 134.62 | 17.70 | 40 | 17865 | 1817 | 64479010 |
Blood bilirubin unconjugated increased | 132.70 | 17.70 | 34 | 17871 | 883 | 64479944 |
Psychiatric decompensation | 131.68 | 17.70 | 42 | 17863 | 2421 | 64478406 |
Eyelid ptosis | 126.94 | 17.70 | 59 | 17846 | 9466 | 64471361 |
Cushing's syndrome | 126.63 | 17.70 | 33 | 17872 | 918 | 64479909 |
Depression suicidal | 119.25 | 17.70 | 39 | 17866 | 2436 | 64478391 |
Foetal death | 115.60 | 17.70 | 48 | 17857 | 5882 | 64474945 |
Pregnancy on contraceptive | 107.99 | 17.70 | 28 | 17877 | 763 | 64480064 |
Osteonecrosis | 104.64 | 17.70 | 76 | 17829 | 28153 | 64452674 |
Ocular icterus | 101.86 | 17.70 | 42 | 17863 | 5056 | 64475771 |
Tearfulness | 98.49 | 17.70 | 40 | 17865 | 4633 | 64476194 |
Pathogen resistance | 94.85 | 17.70 | 53 | 17852 | 12490 | 64468337 |
Adrenal suppression | 93.65 | 17.70 | 28 | 17877 | 1299 | 64479528 |
CD4 lymphocytes decreased | 92.14 | 17.70 | 32 | 17873 | 2403 | 64478424 |
Fanconi syndrome | 91.30 | 17.70 | 32 | 17873 | 2469 | 64478358 |
Drug resistance | 85.89 | 17.70 | 74 | 17831 | 35028 | 64445799 |
Normal newborn | 81.76 | 17.70 | 37 | 17868 | 5580 | 64475247 |
CSF HIV escape syndrome | 77.43 | 17.70 | 18 | 17887 | 307 | 64480520 |
HIV-associated neurocognitive disorder | 77.37 | 17.70 | 18 | 17887 | 308 | 64480519 |
Proteinuria | 77.24 | 17.70 | 63 | 17842 | 27660 | 64453167 |
Blood HIV RNA increased | 73.99 | 17.70 | 24 | 17881 | 1460 | 64479367 |
Drug ineffective | 72.73 | 17.70 | 76 | 17829 | 840171 | 63640656 |
Foetal exposure during pregnancy | 69.99 | 17.70 | 31 | 17874 | 4445 | 64476382 |
Paranoia | 69.80 | 17.70 | 48 | 17857 | 16304 | 64464523 |
Psychomotor skills impaired | 67.85 | 17.70 | 29 | 17876 | 3816 | 64477011 |
Nephropathy toxic | 66.82 | 17.70 | 48 | 17857 | 17466 | 64463361 |
Osteoporosis | 65.32 | 17.70 | 69 | 17836 | 42011 | 64438816 |
Premature rupture of membranes | 65.28 | 17.70 | 28 | 17877 | 3716 | 64477111 |
Lipoatrophy | 65.18 | 17.70 | 18 | 17887 | 627 | 64480200 |
Twin pregnancy | 64.69 | 17.70 | 19 | 17886 | 828 | 64479999 |
Diplopia | 60.60 | 17.70 | 54 | 17851 | 26711 | 64454116 |
Hepatitis | 59.09 | 17.70 | 68 | 17837 | 45514 | 64435313 |
Glycosuria | 58.74 | 17.70 | 22 | 17883 | 2052 | 64478775 |
Depressive symptom | 57.27 | 17.70 | 27 | 17878 | 4469 | 64476358 |
Cortisol decreased | 55.68 | 17.70 | 20 | 17885 | 1657 | 64479170 |
Hypertriglyceridaemia | 55.30 | 17.70 | 36 | 17869 | 11169 | 64469658 |
Placenta praevia | 54.64 | 17.70 | 16 | 17889 | 690 | 64480137 |
Fall | 54.20 | 17.70 | 24 | 17881 | 416802 | 64064025 |
Pain | 53.73 | 17.70 | 45 | 17860 | 553466 | 63927361 |
Pre-eclampsia | 51.71 | 17.70 | 28 | 17877 | 6203 | 64474624 |
Psychotic disorder | 50.67 | 17.70 | 55 | 17850 | 34523 | 64446304 |
Renal failure | 50.55 | 17.70 | 137 | 17768 | 181551 | 64299276 |
Cholelithiasis | 49.33 | 17.70 | 62 | 17843 | 45444 | 64435383 |
Hypophosphataemia | 46.45 | 17.70 | 36 | 17869 | 14684 | 64466143 |
Renal tubular dysfunction | 46.08 | 17.70 | 14 | 17891 | 686 | 64480141 |
Dyspnoea | 44.99 | 17.70 | 82 | 17823 | 718592 | 63762235 |
Mitochondrial cytopathy | 44.52 | 17.70 | 12 | 17893 | 381 | 64480446 |
Ureterolithiasis | 43.18 | 17.70 | 20 | 17885 | 3181 | 64477646 |
Suicidal ideation | 43.15 | 17.70 | 71 | 17834 | 66471 | 64414356 |
Hypotension | 42.07 | 17.70 | 27 | 17878 | 380947 | 64099880 |
Spina bifida | 41.28 | 17.70 | 8 | 17897 | 53 | 64480774 |
Acute kidney injury | 40.24 | 17.70 | 237 | 17668 | 449003 | 64031824 |
Polyhydramnios | 39.31 | 17.70 | 15 | 17890 | 1472 | 64479355 |
Secondary adrenocortical insufficiency | 39.12 | 17.70 | 17 | 17888 | 2328 | 64478499 |
Blood antidiuretic hormone increased | 39.02 | 17.70 | 8 | 17897 | 73 | 64480754 |
Death | 37.97 | 17.70 | 47 | 17858 | 482658 | 63998169 |
Vanishing bile duct syndrome | 37.83 | 17.70 | 14 | 17891 | 1263 | 64479564 |
Placental insufficiency | 37.04 | 17.70 | 13 | 17892 | 1007 | 64479820 |
Peripheral swelling | 36.33 | 17.70 | 7 | 17898 | 209146 | 64271681 |
Hepatic cytolysis | 35.13 | 17.70 | 30 | 17875 | 14019 | 64466808 |
HIV wasting syndrome | 34.23 | 17.70 | 7 | 17898 | 63 | 64480764 |
Joint swelling | 33.82 | 17.70 | 9 | 17896 | 215373 | 64265454 |
Nephrocalcinosis | 33.63 | 17.70 | 13 | 17892 | 1321 | 64479506 |
Hypothalamic pituitary adrenal axis suppression | 33.41 | 17.70 | 9 | 17896 | 285 | 64480542 |
Tubulointerstitial nephritis | 33.32 | 17.70 | 42 | 17863 | 30867 | 64449960 |
Treatment noncompliance | 33.17 | 17.70 | 50 | 17855 | 43432 | 64437395 |
Gestational diabetes | 32.69 | 17.70 | 20 | 17885 | 5570 | 64475257 |
Amniotic cavity infection | 32.51 | 17.70 | 11 | 17894 | 763 | 64480064 |
Psychomotor retardation | 31.62 | 17.70 | 19 | 17886 | 5124 | 64475703 |
CSF virus identified | 31.47 | 17.70 | 6 | 17899 | 36 | 64480791 |
Off label use | 31.44 | 17.70 | 82 | 17823 | 632724 | 63848103 |
Blood corticotrophin decreased | 31.10 | 17.70 | 9 | 17896 | 372 | 64480455 |
Premature baby | 30.82 | 17.70 | 16 | 17889 | 3256 | 64477571 |
Infection | 30.43 | 17.70 | 7 | 17898 | 184873 | 64295954 |
Abdominal discomfort | 29.82 | 17.70 | 7 | 17898 | 182315 | 64298512 |
Ergot poisoning | 29.30 | 17.70 | 7 | 17898 | 135 | 64480692 |
Genotype drug resistance test positive | 29.29 | 17.70 | 11 | 17894 | 1033 | 64479794 |
Syphilis | 29.09 | 17.70 | 9 | 17896 | 469 | 64480358 |
Acute HIV infection | 28.68 | 17.70 | 6 | 17899 | 61 | 64480766 |
Swelling | 28.59 | 17.70 | 5 | 17900 | 160213 | 64320614 |
Cough | 27.52 | 17.70 | 26 | 17879 | 302122 | 64178705 |
Placental disorder | 27.48 | 17.70 | 10 | 17895 | 860 | 64479967 |
Constipation | 27.05 | 17.70 | 15 | 17890 | 229322 | 64251505 |
Acquired immunodeficiency syndrome | 26.13 | 17.70 | 7 | 17898 | 217 | 64480610 |
Placental chorioangioma | 25.99 | 17.70 | 4 | 17901 | 4 | 64480823 |
Nasopharyngitis | 25.89 | 17.70 | 11 | 17894 | 196062 | 64284765 |
Jarisch-Herxheimer reaction | 25.88 | 17.70 | 9 | 17896 | 678 | 64480149 |
Congenital hydrocephalus | 25.56 | 17.70 | 5 | 17900 | 35 | 64480792 |
Subchorionic haematoma | 25.56 | 17.70 | 6 | 17899 | 107 | 64480720 |
Kaposi's sarcoma | 25.12 | 17.70 | 9 | 17896 | 740 | 64480087 |
Crystal urine | 25 | 17.70 | 6 | 17899 | 118 | 64480709 |
Alanine aminotransferase increased | 24.87 | 17.70 | 90 | 17815 | 138941 | 64341886 |
Pneumonia | 24.47 | 17.70 | 77 | 17828 | 559499 | 63921328 |
Dysphagia | 24.31 | 17.70 | 75 | 17830 | 106737 | 64374090 |
Cholestasis | 24.01 | 17.70 | 44 | 17861 | 44828 | 64435999 |
Toxic skin eruption | 23.69 | 17.70 | 28 | 17877 | 19256 | 64461571 |
Conduction disorder | 23.69 | 17.70 | 13 | 17892 | 2955 | 64477872 |
Encephalitis viral | 23.46 | 17.70 | 12 | 17893 | 2368 | 64478459 |
Alpha 1 foetoprotein abnormal | 23.46 | 17.70 | 5 | 17900 | 56 | 64480771 |
Hydronephrosis | 23.41 | 17.70 | 24 | 17881 | 14101 | 64466726 |
Completed suicide | 23.28 | 17.70 | 17 | 17888 | 224397 | 64256430 |
Cholestasis of pregnancy | 23.27 | 17.70 | 9 | 17896 | 916 | 64479911 |
Premature labour | 22.66 | 17.70 | 18 | 17887 | 7602 | 64473225 |
Hepatic cirrhosis | 22.61 | 17.70 | 32 | 17873 | 26266 | 64454561 |
Erythema elevatum diutinum | 22.53 | 17.70 | 4 | 17901 | 15 | 64480812 |
Hepatitis C | 22.53 | 17.70 | 21 | 17884 | 10994 | 64469833 |
Febrile neutropenia | 22.52 | 17.70 | 12 | 17893 | 187645 | 64293182 |
Urinary tract infection | 22.19 | 17.70 | 19 | 17886 | 231577 | 64249250 |
Bilirubin conjugated increased | 22.18 | 17.70 | 15 | 17890 | 4953 | 64475874 |
Disease progression | 22.08 | 17.70 | 6 | 17899 | 141674 | 64339153 |
Encephalitis | 22.01 | 17.70 | 22 | 17883 | 12549 | 64468278 |
Blood creatinine increased | 21.88 | 17.70 | 85 | 17820 | 135697 | 64345130 |
Myoglobin blood increased | 21.84 | 17.70 | 12 | 17893 | 2735 | 64478092 |
Gynaecomastia | 21.83 | 17.70 | 16 | 17889 | 6000 | 64474827 |
Ectopic pregnancy | 21.81 | 17.70 | 10 | 17895 | 1554 | 64479273 |
Adrenal insufficiency | 21.80 | 17.70 | 29 | 17876 | 22458 | 64458369 |
Enanthema | 21.49 | 17.70 | 8 | 17897 | 733 | 64480094 |
Cardiac failure congestive | 21.37 | 17.70 | 5 | 17900 | 130575 | 64350252 |
Renal impairment | 21.33 | 17.70 | 84 | 17821 | 134933 | 64345894 |
ACTH stimulation test abnormal | 21.13 | 17.70 | 4 | 17901 | 23 | 64480804 |
Lipohypertrophy | 20.98 | 17.70 | 8 | 17897 | 784 | 64480043 |
Pancreatitis | 20.77 | 17.70 | 49 | 17856 | 59558 | 64421269 |
Blood pressure increased | 20.76 | 17.70 | 11 | 17894 | 172541 | 64308286 |
Arthralgia | 20.65 | 17.70 | 59 | 17846 | 442201 | 64038626 |
Oligohydramnios | 20.40 | 17.70 | 12 | 17893 | 3112 | 64477715 |
Seborrhoeic dermatitis | 20.33 | 17.70 | 10 | 17895 | 1816 | 64479011 |
Cerebral toxoplasmosis | 20.33 | 17.70 | 10 | 17895 | 1816 | 64479011 |
Mycobacterium avium complex infection | 20.28 | 17.70 | 13 | 17892 | 3927 | 64476900 |
Placental infarction | 20.13 | 17.70 | 5 | 17900 | 114 | 64480713 |
Cytomegalovirus chorioretinitis | 19.97 | 17.70 | 14 | 17891 | 4898 | 64475929 |
Product dose omission issue | 19.87 | 17.70 | 15 | 17890 | 194732 | 64286095 |
Blood lactic acid increased | 19.69 | 17.70 | 19 | 17886 | 10382 | 64470445 |
Portal fibrosis | 19.45 | 17.70 | 7 | 17898 | 583 | 64480244 |
Hyperadrenocorticism | 19.44 | 17.70 | 6 | 17899 | 310 | 64480517 |
Product use issue | 19.26 | 17.70 | 9 | 17896 | 151706 | 64329121 |
Atrial fibrillation | 19.02 | 17.70 | 12 | 17893 | 171077 | 64309750 |
Product use in unapproved indication | 18.81 | 17.70 | 13 | 17892 | 176605 | 64304222 |
Nasal septum deviation | 18.81 | 17.70 | 9 | 17896 | 1539 | 64479288 |
Trimethylaminuria | 18.63 | 17.70 | 5 | 17900 | 156 | 64480671 |
Cushingoid | 18.53 | 17.70 | 16 | 17889 | 7587 | 64473240 |
Pain in extremity | 18.51 | 17.70 | 35 | 17870 | 303050 | 64177777 |
Aspartate aminotransferase increased | 18.49 | 17.70 | 74 | 17831 | 119714 | 64361113 |
Renal tubular acidosis | 18.30 | 17.70 | 11 | 17894 | 2968 | 64477859 |
Acute stress disorder | 18.01 | 17.70 | 6 | 17899 | 397 | 64480430 |
None
Source | Code | Description |
---|---|---|
ATC | J05AE08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Protease inhibitors |
ATC | J05AR15 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
ATC | J05AR23 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
FDA MoA | N0000000246 | HIV Protease Inhibitors |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D017320 | HIV Protease Inhibitors |
MeSH PA | D011480 | Protease Inhibitors |
MeSH PA | D000084762 | Viral Protease Inhibitors |
FDA EPC | N0000175889 | Protease Inhibitor |
FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
FDA MoA | N0000187062 | Cytochrome P450 2C8 Inhibitors |
FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
FDA MoA | N0000191269 | UDP Glucuronosyltransferases Inhibitors |
FDA MoA | N0000191272 | UGT1A1 Inhibitors |
CHEBI has role | CHEBI:35660 | HIV protease inhibitors |
CHEBI has role | CHEBI:36044 | antiviral drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Prevention of HIV Infection after Exposure | off-label use | ||
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Hepatic failure | contraindication | 59927004 | |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Hemophilia | contraindication | 90935002 | |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Kidney stone | contraindication | 95570007 | |
Chronic hepatitis C | contraindication | 128302006 | |
Liver function tests abnormal | contraindication | 166603001 | |
Atrioventricular block | contraindication | 233917008 | DOID:0050820 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.91 | acidic |
pKa2 | 11.57 | acidic |
pKa3 | 4.94 | Basic |
pKa4 | 1.0 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 300MG BASE;150MG | EVOTAZ | BRISTOL-MYERS SQUIBB | N206353 | Jan. 29, 2015 | RX | TABLET | ORAL | 8148374 | Sept. 3, 2029 | TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Multidrug resistance protein 1 | Transporter | IC50 | 4.17 | CHEMBL | |||||
Cytochrome P450 2C9 | Enzyme | Ki | 4.92 | WOMBAT-PK | |||||
Cytochrome P450 1A2 | Enzyme | Ki | 4.92 | WOMBAT-PK | |||||
UDP-glucuronosyltransferase 1-1 | Enzyme | Ki | 5.72 | WOMBAT-PK | |||||
Cytochrome P450 3A4 | Enzyme | Ki | 5.63 | WOMBAT-PK | |||||
Pol polyprotein | Enzyme | INHIBITOR | Ki | 9.62 | CHEMBL | CHEMBL | |||
Gag-Pol polyprotein | Polyprotein | Ki | 8.58 | WOMBAT-PK | |||||
Reverse transcriptase/RNaseH | Enzyme | IC50 | 7.59 | CHEMBL | |||||
Protease | Enzyme | IC50 | 8.40 | CHEMBL | |||||
Protease | Unclassified | Ki | 10.27 | CHEMBL | |||||
Protease | Unclassified | Ki | 10.12 | CHEMBL |
ID | Source |
---|---|
4024316 | VUID |
N0000022320 | NUI |
D01276 | KEGG_DRUG |
229975-97-7 | SECONDARY_CAS_RN |
343047 | RXNORM |
C1176383 | UMLSCUI |
CHEBI:37924 | CHEBI |
DR7 | PDB_CHEM_ID |
CHEMBL1163 | ChEMBL_ID |
CHEMBL1200678 | ChEMBL_ID |
D000069446 | MESH_DESCRIPTOR_UI |
DB01072 | DRUGBANK_ID |
11138 | IUPHAR_LIGAND_ID |
8181 | INN_ID |
QZU4H47A3S | UNII |
148192 | PUBCHEM_CID |
17380 | MMSL |
267545 | MMSL |
30601 | MMSL |
46998 | MMSL |
d04882 | MMSL |
000306 | NDDF |
000539 | NDDF |
4021397 | VANDF |
4024316 | VANDF |
404838006 | SNOMEDCT_US |
413591007 | SNOMEDCT_US |
413592000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3622 | CAPSULE, GELATIN COATED | 300 mg | ORAL | NDA | 29 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3624 | CAPSULE, GELATIN COATED | 150 mg | ORAL | NDA | 29 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3631 | CAPSULE, GELATIN COATED | 200 mg | ORAL | NDA | 29 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3638 | POWDER | 50 mg | ORAL | NDA | 29 sections |
EVOTAZ | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0003-3641 | TABLET | 300 mg | ORAL | NDA | 30 sections |
EVOTAZ | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0003-3641 | TABLET | 300 mg | ORAL | NDA | 30 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5526 | CAPSULE | 150 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5526 | CAPSULE | 150 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5527 | CAPSULE | 200 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5527 | CAPSULE | 200 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5528 | CAPSULE | 300 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5528 | CAPSULE | 300 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6875 | CAPSULE | 300 mg | ORAL | ANDA | 27 sections |
Atazanavir Sulfate | Human Prescription Drug Label | 1 | 16714-860 | CAPSULE | 150 mg | ORAL | ANDA | 27 sections |
Atazanavir Sulfate | Human Prescription Drug Label | 1 | 16714-861 | CAPSULE | 200 mg | ORAL | ANDA | 27 sections |
Atazanavir Sulfate | Human Prescription Drug Label | 1 | 16714-862 | CAPSULE | 300 mg | ORAL | ANDA | 27 sections |
Atazanavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-653 | CAPSULE | 150 mg | ORAL | ANDA | 29 sections |
Atazanavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-654 | CAPSULE | 200 mg | ORAL | ANDA | 29 sections |
Atazanavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-655 | CAPSULE | 300 mg | ORAL | ANDA | 29 sections |
Atazanavir | Human Prescription Drug Label | 1 | 42385-920 | CAPSULE | 150 mg | ORAL | ANDA | 27 sections |
Atazanavir | Human Prescription Drug Label | 1 | 42385-921 | CAPSULE | 200 mg | ORAL | ANDA | 27 sections |
Atazanavir | Human Prescription Drug Label | 1 | 42385-922 | CAPSULE | 300 mg | ORAL | ANDA | 27 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-171 | CAPSULE | 150 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-172 | CAPSULE | 200 mg | ORAL | ANDA | 28 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-173 | CAPSULE | 300 mg | ORAL | ANDA | 28 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4854 | CAPSULE, GELATIN COATED | 200 mg | ORAL | NDA | 27 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4857 | CAPSULE, GELATIN COATED | 150 mg | ORAL | NDA | 27 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5838 | CAPSULE, GELATIN COATED | 300 mg | ORAL | NDA | 27 sections |
Atazanavir Sulfate | Human Prescription Drug Label | 1 | 65862-710 | CAPSULE | 100 mg | ORAL | ANDA | 27 sections |
Atazanavir Sulfate | Human Prescription Drug Label | 1 | 65862-711 | CAPSULE | 150 mg | ORAL | ANDA | 27 sections |